Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

QNTM stock hub

Quantum BioPharma Ltd. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

QNTMis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

28.5M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

QNTM

In the news

Latest news · QNTM

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-2,056.5

P25 -105.6P50 -46.5P75 -3.1

ROIC-353.4

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All QNTM market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

169

Groups with data

Currency

USD

Showing 169 of 169 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001771885
Company name	Quantum BioPharma Ltd.
Country	Canada
Country code	US
Employees	17
Employees Change	7%
Employees Change Percent	70
Enterprise value	$22.7M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	CA74764Y2050
Last refreshed	2026-05-10
Market cap	$28.5M
Market cap category	Nano-Cap
Price	$4.88
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	QNTM
Website	https://www.quantumbiopharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-109.21%
FCF yield	-28.87%

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-31.2M
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Profit Per Employee	$-1.8M
ROA	-62.38
Roa5y	-48.6
ROCE	1,047.3
ROE	-2,056.5
Roe5y	-139.3
ROIC	-353.4

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-42%
Cagr3y	-61.44%
Cagr5y	-46.42%
EPS Growth Quarters	3
EPS Growth Years	6
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$14.9M
Cash	$4.6M
Current Assets	$6.5M
Current Liabilities	$6.1M
Debt	$870,057
Equity	$-1.4M
Interest Coverage	-6.81
Liabilities	$16.3M
Long Term Assets	$8.4M
Long Term Liabilities	$10.3M
Net Cash	$3.7M
Net Cash By Market Cap	$12.95
Net Cash Growth	-92.34%
Tangible Book Value	$-3.8M
Tangible Book Value Per Share	$-0.85
WACC	11.93

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.63
Net Working Capital	$-9.7M
Quick ratio	0.29
Working Capital	$-6M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-189.02%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-41.97%
200-day SMA	10.14
3Y total return	-94.27%
50-day SMA	3.76
50-day SMA vs 200-day SMA	50under200
5Y total return	-95.58%
All Time High	11,431.9
All Time High Change	-99.96%
All Time High Date	2018-09-10
All Time Low	2.07
All Time Low Change	135.75%
All Time Low Date	2026-03-11
ATR	0.65
Beta	0.36
Ch YTD	-33.15
High	5.01
High52	38.25
High52 Date	2025-06-20
High52ch	-87.24%
Low	4.7
Low52	2.07
Low52 Date	2026-03-11
Low52ch	135.75%
Ma50ch	29.79%
Premarket Change Percent	-1.8
Premarket Price	$4.92
Premarket Volume	2,044
Price vs 200-day SMA	-51.85%
RSI	56.59
RSI Monthly	38.7
RSI Weekly	44.88
Sharpe ratio	0.35x
Sortino ratio	0.66
Total Return	-189.02%
Tr YTD	-33.15
Tr1m	25.77%
Tr1w	-12.07%
Tr3m	16.19%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Earnings EPS Estimate	$-0.56
Earnings Revenue Estimate	1,496,000x
Operating Income	$-14.9M

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	5,362,502%
Float Percent	119.45%
Net Borrowing	3,745,089
Shares Insiders	8.01%
Shares Institutions	10.46%
Shares Out	4,489,451
Shares Qo Q	0.81%
Shares Yo Y	189.02%
Short Float	3.37%
Short Ratio	0.31
Short Shares	4.03

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-11.8M
Average Volume	424,885.95x
Bv Per Share	0.13
Ch1m	25.77
Ch1w	-12.07
Ch1y	-41.97
Ch3m	16.19
Ch3y	-94.27
Ch5y	-95.58
Ch6m	-45.23
Change	-2.59%
Change From Open	-1.01
Close	5.01
Days Gap	-1.6
Depreciation Amortization	545,780
Dollar Volume	575,317.8
Earnings Date	2026-05-22
Earnings Time	amc
EBIT	$-14.9M
EBITDA	$-14.3M
EPS	$-8.23
F Score	1
FCF	$-8.2M
FCF EV Yield	-36.27x
FCF Per Share	$-1.83
Financing CF	9,964,033
Fiscal Year End	December
Founded	1,998
Investing CF	-3,495,520
Is Primary Listing	0
Is Spac	No
Last Earnings Date	2026-03-26
Last Report Date	2025-12-31
Last Split Date	2024-08-15
Last Split Type	Reverse
Last10k Filing Date	2026-03-26
Ma150	7
Ma150ch	-30.29%
Ma20	4.25
Ma20ch	14.9%
Net CF	823,595
Next Earnings Date	2026-05-22
Open	4.93
Optionable	No
Position In Range	58.06
Post Close	4.88
Postmarket Change Percent	2.05
Postmarket Price	$4.98
Ppne	169,349
Pre Close	5.01
Price Date	2026-05-08
Relative Volume	0.28x
Share Based Comp	3,546,287
Tr6m	-45.23%
Volume	117,893

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does QNTM pay a dividend?

Capital-return profile for this ticker.

Performance

QNTM stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns QNTM?

Insider, institutional, and short-interest positioning.

Institutional ownership

+10.5%

Float: +119.4% of shares outstanding

Insider ownership

+8.0%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

QNTM momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

56.6

Neutral momentum band

Price vs 200-day MA

-51.9%

50/200-day relationship not available

Beta (5Y)

0.36

Less volatile than the market

Sharpe ratio

0.35

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About QNTM

Hub-level FAQ points readers to the deeper analysis pages.

What is the current QNTM stock rating?

Quantum BioPharma Ltd. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full QNTM analysis?

The full report lives at /stocks/QNTM/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for QNTM?

The latest report frames QNTM around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the QNTM page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.